Phaseline

Targets › F8

F8 (Coagulation factor VIII): drug programs, companies and trials

22 programs from 20 companies in 31 trials: 15 Phase 3, 8 Phase 4, 7 Phase 1, 1 Phase 2; Hematology, Other; next expected readout Nov 2026.

Factor VIII, along with calcium and phospholipid, acts as a cofactor for F9/factor IXa when it converts F10/factor X to the activated form, factor Xa. (UniProt, P00451)

Open in Phaseline: the race on F8, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Swedish Orphan BiovitrumEfanesoctocog alfa
Coagulation factor VIII exogenous protein
F8Phase 4Haemophilia A (Moderate or Severe); Hemophilia ANov 2026
OctapharmaSimoctocog Alfa
Coagulation factor VIII exogenous protein
F8Phase 4Severe Hemophilia A; Hemophilia AFeb 2027
University Hospital, Basel, SwitzerlandWilate
1:1 balanced mixture of von Willebrand Factor and Coagulation Factor VIII
F8, VWFPhase 4BleedingNov 2027
Runhui WUOctocog Alfa
Coagulation factor VIII exogenous protein
F8Phase 4Hemophilia a with InhibitorMar 2028
Grifols BiologicalsAlphanate SD/HT
Factor VIII/von Willebrand Factor (vWF) concentrate
F8, VWFPhase 4Von Willebrand Disease–
Gritgen TherapeuticsGS1191-0445 injection
AAV8-delivered gene therapy expressing B-domain deleted human factor VIII (FVIII)
F8Phase 3Hemophilia A; Severe Hemophilia ANov 2026
Bioverativ, a Sanofi companyEfanesoctocog Alfa (BIVV001)
Coagulation factor VIII exogenous protein
F8Phase 3Hemophilia AJan 2027
Hangzhou Gensciences BiopharmaceuticalFRSW107
Recombinant human coagulation Factor VIII-Fc fusion protein
F8Phase 3Severe Hemophilia AFeb 2027
RocheNXT007
Factor VIII mimetic/extended half-life factor VIII replacement
F8Phase 3Hemophilia ASep 2027
Unity Health TorontoWilate
Von Willebrand Factor and Factor VIII concentrate
VWF, F8Phase 3Von Willebrand DiseasesDec 2027
Novo NordiskDenecimig (Mim8)
Recombinant Factor VIII replacement
F8Phase 3Haemophilia AJun 2028
SinocelltechOmfiloctocog Alfa (SCT800)
Coagulation factor VIII exogenous protein
F8Phase 3Haemophilia A; Hemophilia A With InhibitorDec 2028
Pfizergiroctocogene fitelparvovec
AAV5 gene therapy delivering factor VIII
F8Phase 3Hemophilia AFeb 2040
CSL BehringLonoctocog Alfa
Coagulation factor VIII exogenous protein
F8Phase 3Congenital Hemophilia A–
PfizerPF-07055480 / Giroctocogene Fitelparvovec
Recombinant AAV2/6 human Factor VIII gene therapy
F8Phase 3Hemophilia A–
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalRecombinant human coagulation factor VIII for injection
Recombinant human coagulation factor VIII (replacement therapy)
F8Phase 3Hemophilia A–
Shanghai Xinzhi BioMedBBM-H803
AAV vector expressing human factor VIII transgene
F8Phase 2Hemophilia AMay 2027
ASC TherapeuticsASC618
AAV vector encoding B-domain deleted codon-optimized human factor VIII
F8Phase 1Hemophilia ADec 2026
Medical College of WisconsinPleightlet(MUT6)
Lentiviral vector encoding B-domain-deleted human coagulation factor VIII (BDDFVIII) for p
F8Phase 1Hemophilia AMar 2027
University College, LondonAAV2/8-HLP-FVIII-V3
AAV2/8-mediated gene transfer of coagulation factor VIII
F8Phase 1Hemophilia AJan 2029
RocheSPK-8011QQ (RO7878488)
Gene therapy for Factor VIII deficiency
F8Phase 1Hemophilia AApr 2032
BiocadANB-010
Adeno-associated viral vector carrying the FVIII gene
F8Phase 1Hemophilia AJun 2033

Conditions

Hemophilia A (16) Severe Hemophilia A (4) Haemophilia A (3) Haemophilia A (Moderate or Severe) (2) Hemophilia A With Inhibitor (1) Von Willebrand Diseases (1) Hemophilia a with Inhibitor (1) Bleeding (1) Von Willebrand Disease (1) Congenital Hemophilia A (1)

Modalities

small molecule (9), other (5), protein or peptide (5), mixed (1), antibody (1)

Companies

Pfizer (2) Roche (2) Swedish Orphan Biovitrum (1) Medical College of Wisconsin (1) Sinocelltech (1) Octapharma (1) University College, London (1) Unity Health Toronto (1) ASC Therapeutics (1) Bioverativ, a Sanofi company (1) Biocad (1) Hangzhou Gensciences Biopharmaceutical (1) Gritgen Therapeutics (1) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (1) Runhui WU (1) Shanghai Xinzhi BioMed (1) University Hospital, Basel, Switzerland (1) Novo Nordisk (1) Grifols Biologicals (1) CSL Behring (1)

Related targets

VWF (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.